Results 71 to 80 of about 2,223,665 (257)

HSP90α Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia

, 2021
As one of the most common malignancies worldwide, Hepatocellular carcinoma (HCC) has been treated by Sorafenib, which is the first approved target drug by FDA for advanced HCC. However, drug resistance is one of the obstacles to its application.
Yue Yang, Jia Li, Di Pan, Yuting Ye, Yan Liao, Heng Zhang, Youxiang Ding, Li Zhao   +7 more
core   +1 more source

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma

Journal of Translational Medicine
Background Sorafenib resistance is becoming increasingly common and disadvantageous for hepatocellular carcinoma (HCC) treatment. Ferroptosis is an iron dependent programmed cell death underlying the mechanism of sorafenib.
Xiuya Hu, Peiyu Zhang, Sai Li, Jiaqi Zhang, Danni Wang, Zihan Wang, Lu Zhu, Lingdi Wang   +7 more
doaj   +1 more source

Integrated PANoptosis Profiling Identifies Immunosuppressive Subtypes and a Prognostic Signature With Functional Validation of MLKL in Glioblastoma

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The prognosis of glioblastoma (GBM) remains highly unfavorable, largely due to high tumor heterogeneity and an immunosuppressive microenvironment. However, the functional role of PANoptosis in this context is poorly understood. Methods Patients were stratified via K‐means clustering. A risk score model was constructed using prognosis‐
Langfei Tian, Minghui Zhao, Yuanbo Hu, Kaiyue Wang, Haiguang Liu, Zetong Bai, Kebin Zheng   +6 more
wiley   +1 more source

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Frontiers in Pharmacology, 2022
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib ...
Zhi-Yong Liu, Zhi-Yong Liu, Dan-Ying Zhang, Dan-Ying Zhang, Xia-Hui Lin, Xia-Hui Lin, Jia-Lei Sun, Jia-Lei Sun, Weinire Abuduwaili, Weinire Abuduwaili, Guang-Cong Zhang, Guang-Cong Zhang, Ru-Chen Xu, Ru-Chen Xu, Fu Wang, Fu Wang, Xiang-Nan Yu, Xiang-Nan Yu, Xuan Shi, Xuan Shi, Bin Deng, Ling Dong, Ling Dong, Shu-Qiang Weng, Shu-Qiang Weng, Ji-Min Zhu, Ji-Min Zhu, Xi-Zhong Shen, Xi-Zhong Shen, Xi-Zhong Shen, Tao-Tao Liu, Tao-Tao Liu   +31 more
doaj   +1 more source

HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters

International Journal of Genomics, 2022
Hepatocellular carcinoma (HCC) represents a common malignancy, and mechanisms of acquired sorafenib resistance during the treatment of HCC patients remain elusive.
Xian Zhu, Yinfang Zhang, Yafei Wu, Wenjing Diao, Guilong Deng, Qin Li, Chuanxing Wu   +6 more
doaj   +1 more source

Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment

Advanced Science, EarlyView.
Combinations of small activating RNAs and small interfering RNAs were developed as personalized precision therapies that simultaneously activate tumor suppressors and silence oncogenes according to the molecular signatures of patient tumors. This combination strategy demonstrated superior anticancer efficacy, highlighting the promise of precision ...
Jing Wu, Jiaxuan Chen, Abdechakour Elkihel, Wenjun Lan, Nicolas Fraunhoffer, Dandan Zhu, Baoping Lian, Christina Galanakou, Zhancun Bian, Xi Liu, Odile Gayet, Loic Moubri, Julie Aglietti Roques, Vikash Reebye, Nagy Habib, Xiaoxuan Liu, Nelson Dusetti, Juan Lucio Iovanna, Ling Peng   +18 more
wiley   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis [PDF]

Hepatology, 2016
Hepatocellular carcinoma (HCC) is a major cause of cancer‐related death worldwide and currently has the fastest rising incidence of all cancers. Sorafenib was originally identified as an inhibitor of multiple oncogenic kinases and remains the only approved systemic therapy for advanced HCC.
Xiaofang, Sun, Xiaohua, Niu, Ruochan, Chen, Wenyin, He, De, Chen, Rui, Kang, Daolin, Tang   +6 more
openaire   +2 more sources

DLST Succinylation‐Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma

Advanced Science, EarlyView.
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li, Peijun Zhou, Xingzhi Peng, Qixin Liu, Wenhui Zeng, Rui Wang, Liangfang Shen, Jinwu Peng, Qin Zhou, Lifang Yang   +9 more
wiley   +1 more source